Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tovbis-Shifrin N"'
Autor:
Araujo HA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pechuan-Jorge X; Revolution Medicines, Redwood City, California., Zhou T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Do MT; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hu X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rojas Alvarez FR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Salvatierra ME; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ibarguen HP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Raghulan R; Revolution Medicines, Redwood City, California., Shah H; Revolution Medicines, Redwood City, California., Moreno Ayala MA; Revolution Medicines, Redwood City, California., Chen K; Revolution Medicines, Redwood City, California., Tovbis Shifrin N; Revolution Medicines, Redwood City, California., Wu S; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Negrao MV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jiang J; Revolution Medicines, Redwood City, California., Singh M; Revolution Medicines, Redwood City, California., Smith JAM; Revolution Medicines, Redwood City, California., Quintana E; Revolution Medicines, Redwood City, California., Skoulidis F; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2183-2208.
Autor:
Raghavan S; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States.; Department of Microbiology and Immunology, Institute for Biomedicine, University of Gothenburg, Gothenburg, Sweden., Tovbis-Shifrin N; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Kochel C; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Sawant A; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Mello M; Centre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille Université (UMS3367), National Institute of Health and Medical Research (INSERM) (US012), The French National Centre for Scientific Research (CNRS) (UMS3367), Marseille, France., Sathe M; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Blumenschein W; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Muise ES; Merck & Co., Inc., Boston, MA, United States., Chackerian A; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Pinheiro EM; Merck & Co., Inc., Boston, MA, United States., Rosahl TW; Merck & Co., Inc., Kenilworth, NJ, United States., Luche H; Centre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille Université (UMS3367), National Institute of Health and Medical Research (INSERM) (US012), The French National Centre for Scientific Research (CNRS) (UMS3367), Marseille, France., de Waal Malefyt R; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States.
Publikováno v:
Frontiers in immunology [Front Immunol] 2021 Nov 29; Vol. 12, pp. 752348. Date of Electronic Publication: 2021 Nov 29 (Print Publication: 2021).